Kim Ji-Hoon, Kim Hyunil, Kim Jin Woo, Kim Hee Man
Department of Medicine, Yonsei University Wonju College of Medicine, Wonju 26426, Korea.
Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju 26426, Korea.
J Clin Med. 2021 Sep 20;10(18):4258. doi: 10.3390/jcm10184258.
Signet-ring cell carcinoma (SRCC) is a rare histopathological subtype of colorectal cancer (CRC) constituting approximately 1% of CRC cases. This study analyzed the incidence and survival rates of colorectal SRCC.
We analyzed the incidence and survival rates of colorectal SRCCs based on patients' data of the Korea Central Cancer Registry.
The age-standardized incidence rates of colon and rectum SRCC in 2017 were 0.17 and 0.07 individuals per 100,000, respectively. Between 1993 and 2017, the 1-, 2-, 3-, 4-, and 5-year relative survival rates of patients with colon SRCC were 65.6%, 49.0%, 38.9%, 34.9%, and 33.0%, respectively, while those of patients with rectum SRCC were 69.6%, 47.8%, 38.5%, 32.8%, and 29.4%, respectively. According to the Surveillance, Epidemiology, and End Results summary stages, the 5-year relative survival rates of colon SRCC between 1993 and 2017 were 70.4% for the localized stage, 41.0% for the regional stage, and 7.0% for the distant stage, while those for rectum SRCC were 60.7%, 34.4, and 3.3%, respectively.
Although the incidence of colorectal SRCC is extremely low in South Korea, it has been increasing in recent decades. As the prognosis of colorectal SRCC is extremely poor; clinicians should be aware of the differential diagnosis of SRCC in colorectal cancer cases.
印戒细胞癌（SRCC）是结直肠癌（CRC）一种罕见的组织病理学亚型，约占CRC病例的1%。本研究分析了结直肠SRCC的发病率和生存率。
我们基于韩国中央癌症登记处患者的数据，分析了结直肠SRCC的发病率和生存率。
2017年结肠和直肠SRCC的年龄标准化发病率分别为每10万人0.17例和0.07例。1993年至2017年期间，结肠SRCC患者的1年、2年、3年、4年和5年相对生存率分别为65.6%、49.0%、38.9%、34.9%和33.0%，而直肠SRCC患者的相应生存率分别为69.6%、47.8%、38.5%、32.8%和29.4%。根据监测、流行病学和最终结果总结分期，1993年至2017年期间，结肠SRCC局限期的5年相对生存率为70.4%，区域期为41.0%，远处转移期为7.0%，而直肠SRCC的相应生存率分别为60.7%、34.4%和3.3%。
尽管韩国结直肠SRCC的发病率极低，但近几十年来一直在上升。由于结直肠SRCC的预后极差，临床医生应注意结直肠癌病例中SRCC的鉴别诊断。
